"Towards a Future Without Injections" — Australian-Developed "Smart Insulin Pill" to Enter Clinical Trials Next Year

1 Introduction: A Dream Over 100 Years

A century has passed since the discovery of insulin in 1922. Technology has made needles thinner and brought pumps and CGMs into practical use, but "oral insulin" has yet to be realized. Overcoming the barrier of proteins easily broken down by stomach acid, Sydney's Endo Axiom has finally reached the brink of human trials 9news.com.au.

2 Endo Axiom's Technology: Three-Layer Nano-Carrier and "Smart" Control

The company's tablet features a three-layer structure: ① Outer shell: acid-resistant polymer, ② Intermediate layer: enzyme-sensitive membrane, ③ Inner core: liposome-encapsulated insulin. It is designed to open the shell triggered by a glucose-responsive enzyme activated when blood sugar is high, releasing insulin in the liver via the portal system. CEO Nicholas Hunt proudly states, "We are the first in the world to make 'smart insulin' that turns on only during hyperglycemia and off during hypoglycemia, available orally" 9news.com.au.

3 Clinical Plans and Public Support

Safety and efficacy will be confirmed in two phases: Phase 1a (healthy individuals) → 1b (T1D patients). The government's BioMedTech Horizons program has granted the company 1 million AUD, supporting 14 companies with a total of 12 million AUD 9news.com.au. Health Minister Butler emphasizes, "We will not let domestic innovations flow overseas."

4 Why Oral Insulin is Challenging

Past attempts (such as Oramed, Biocon's Tregopil) have struggled with low absorption rates, individual differences, and controlling hypoglycemia risk clinicalresearchnewsonline.comen.wikipedia.org. Endo Axiom's new approach targets the hepatic portal route to utilize the first-pass effect, suppressing systemic exposure and preventing hypoglycemia.

5 Interpreting Reactions on Social Media

• Excited Group: "Can't believe the day of being free from injections is coming!" "Less guilt about sticking needles into children."

• Cost-Focused Group: "If the drug price is high, it’s meaningless." "Whether it gets listed on PBS (Pharmaceutical Benefits Scheme) is key."

• Cautious Group: "Will those with gastrointestinal diseases have differences in absorption?" "Worried about long-term immune responses."
  Diabetes Australia’s official X welcomes, saying, "It's wonderful that world-class research is moving to the next stage." twitter.com. Meanwhile, the U.S. DIY diabetes community continues to evaluate the technology, asking, "Does it really stop 'on-demand'? Want to compare with CGM data."

  • 
    

6 Current Status of Competing Technologies

• Inhaled Type Afrezza: Reports show HbA1c improvement equivalent to injections even in children reuters.com

• Weekly Type Insulin (Efsitora, Icodec): Suggests improved adherence and weight gain suppression reuters.comen.wikipedia.org

• Cell Therapy (Stem Cell derived islets, Lantidra): While there are reports of cases becoming insulin-independent, challenges with immunosuppression remain nypost.comen.wikipedia.org

These represent different strategies such as "administration frequency," "route of administration," and "β-cell replacement," with oral agents uniquely positioned to be minimally invasive and facilitate self-management.

7 Economics and Access

The global insulin market was approximately $22.9 billion in 2020, with biosimilars accounting for $2.3 billion en.wikipedia.org. Considering the total costs including syringes, pumps, and CGMs, tablets that can be stored at room temperature and mass-produced may have the potential to scale easily to low- and middle-income countries.

8 Regulation and Ethics

Oral administration of biologically derived proteins is expected to have a simplified path for Biological License Application (BLA), but safety monitoring is essential for T1D with an autoimmune background. Patient groups point out the risk that development could halt with a single hypoglycemic incident, even if high efficacy is demonstrated.

9 Future Milestones

10 Conclusion: Roadmap to a Zero-Injection Society

The pain and psychological burden of insulin injections are among the biggest factors undermining treatment adherence. If oral insulin becomes practical, it could dramatically lower the threshold for self-management and enhance the quality of life and work. However, the implementation of the "dream pill" requires simultaneously meeting the three conditions of safety, consistent absorption, and price. The human trials starting in late 2025 will likely be the true litmus test of its feasibility.